Author

M. A. Gray

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Cell Biology· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Research Focus:drug response / drug discovery· 4 Organism:mouse· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Organism:human· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell-cell communication· 1

Frequent Co-Authors

C. R. Bertozzi· 2 shared A. de Janon· 1 shared A. Mantalaris· 1 shared A. Petrone· 1 shared A. S. Kashyap· 1 shared A. Zippelius· 1 shared B. Bruncsics· 1 shared B. Kasenda· 1 shared

Activity by Year

2018-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

C. R. Bertozzi

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Intracellular biomacromolecule delivery by stimuli responsive protein vesicles loaded by hydrophobic ion pairing

M. A. Gray, A. de Janon, M. Seeler, W. T. Heller, N. Panoskaltsis, A. Mantalaris, J. A. Champion

This study develops stimuli-responsive protein vesicles using hydrophobic ion pairing to deliver proteins and siRNA, showing effective delivery and functional activity in cancer cell lines and organoid models.

ACS Omega · Jan 14, 2025Peer-reviewedBioengineering

Antibody-lectin chimeras for glyco-immune checkpoint blockade

J. C. Stark, M. A. Gray, S. Wisnovsky, I. Ibarlucea-Benitez, M. Lustig, N. M. Riley, M. K. Ribi, W. J. Errington, B. Bruncsics, C. A. Sarkar, T. Valerius, J. V. Ravetch, C. R. Bertozzi

This paper introduces antibody-lectin chimeras (AbLecs) as a new immunotherapy approach that blocks glyco-immune checkpoints, enhancing cancer immune responses and synergizing with existing checkpoint inhibitors.

bioRxiv · Oct 26, 2022Bioengineering

Drug repurposing for Cystic Fibrosis: identification of drugs that induce CFTR-independent fluid secretion in nasal organoids

L. W. Rodenburg, L. Delpiano, V. Railean, R. Centeio, M. C. Pinto, S. M. A. Smits, I. S. van der Windt, C. F. J. van Hugten, S. F. B. van Beuningen, R. N. P. Rodenburg, C. K. van der Ent, M. D. Amaral, K. Kunzelmann, M. A. Gray, J. M. Beekman, G. D. Amatngalim

This study identifies 12 FDA-approved drugs that induce CFTR-independent fluid secretion in nasal organoids, offering potential treatment for CF patients unresponsive to CFTR modulators.

bioRxiv · Sep 23, 2022Cell Biology

Targeting cancer glycosylation repolarizes tumor-associated macrophages allowing effective immune checkpoint blockade

M. A. Stanczak, N. R. Mantuano, N. Kirchhammer, D. E. Sanin, J. Wang, M. P. Trefny, G. Monaco, M. A. Gray, A. Petrone, A. S. Kashyap, K. Glatz, B. Kasenda, K. Normington, J. Broderick, L. Peng, , H. Laeubli

This study shows that targeting cancer glycosylation with an antibody-sialidase conjugate repolarizes tumor-associated macrophages and enhances immune checkpoint blockade efficacy in mouse models.

bioRxiv · Apr 11, 2021Immunology

Lysosome enlargement during inhibition of the lipid kinase PIKfyve proceeds through lysosome coalescence

C. H. Choy, G. Saffi, M. A. Gray, C. Wallace, R. M. Dayam, Z.-Y. A. Ou, G. Lenk, R. Puertollano, S. C. Watkins, R. J. Botelho

This study shows that PIKfyve inhibition causes lysosome coalescence, leading to fewer enlarged lysosomes, and that TFEB-mediated biosynthesis does not drive this swelling.

bioRxiv · Apr 5, 2018Cell Biology